Oncology Pharmacy Specialty Review Course, Workbook Chapters (No Recert Credit (Cert # L219097)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/03/2021
Content Release Date: 03/17/2021
Expiration Date: 02/15/2022
Activity Type: Application-based
CE Credits: 25.75 hours (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Oncology Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of oncology issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here: http://elearning.ashp.org/catalog/onc-recert

These activities are part of the ASHP and ACCP professional development program.

Review Course

This course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios and links to the reference sources, and domains, tasks, and knowledge statements.      

  

Learning Module

ACPE Number

Credit Hours

ACPE Expiration Date

Breast Cancer

0204-9999-21-922-H01-P

2.50

03/17/2024

Gynecologic Malignancies

0204-9999-21-914-H01-P

1.00

03/17/2024

Prostate Cancer

0204-9999-21-916-H01-P

1.00

03/17/2024

Pediatric Malignancies and Supportive Care

0204-9999-21-926-H01-P

1.25

03/17/2024

Upper Gastrointestinal and Hepatocellular Carcinomas

0204-9999-21-924-H01-P

0.75

03/17/2024

Bladder, Renal Cell, and Testicular Cancers

0204-9999-21-929-H01-P

1.00

03/17/2024

Melanoma and Non-Melanoma Skin Cancers

0204-9999-21-915-H01-P

1.00

03/17/2024

Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-21-912-H04-P

2.00

03/17/2024

Adult Acute Leukemias and Myelodysplastic Syndromes

0204-9999-21-928-H01-P

1.50

03/17/2024

Lymphomas

0204-9999-21-925-H01-P

1.25

03/17/2024

Chronic Leukemias

0204-9999-21-917-H01-P

1.50

03/17/2024

Hematopoietic Stem Cell Transplantation

0204-9999-21-921-H01-P

1.25

03/17/2024

Lung Cancer

0204-9999-21-923-H01-P

1.50

03/17/2024

Lower Gastrointestinal and Pancreatic Cancers

0204-9999-21-927-H01-P

1.25

03/17/2024

Head, Neck and Adult Central Nervous System (CNS) Malignancies

0204-9999-21-930-H01-P

1.00

03/17/2024

Cancer-related Infectious Diseases

0204-9999-21-931-H01-P

1.00

03/17/2024

Oncology Practice Management

0204-9999-21-920-H04-P

2.00

03/17/2024

Multiple Myeloma

0204-9999-21-918-H01-P

1.50

03/17/2024

Adult Sarcoma

0204-9999-21-919-H01-P

0.75

03/17/2024

Pharmacogenomics in Oncology

0204-9999-21-913-H01-P

0.75

03/17/2024

Learning Objectives

At the end of the presentations, the pharmacist should be able to:

ACPE #: 0204-9999-21-922-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

ACPE #: 0204-9999-21-914-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
  • Discuss short and long-term goals, including post-therapy and survivorship, for a patient with a gynecologic malignancy and her caregiver.
  • Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening).

ACPE #: 0204-9999-21-916-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Identify appropriate diagnostic, prognostic, and monitoring tests for a patient with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

ACPE #: 0204-9999-21-926-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
  • Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

ACPE #: 0204-9999-21-924-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

ACPE #: 0204-9999-21-929-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular cancer and his or her caregiver
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.

ACPE #: 0204-9999-21-915-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with melanoma.
  • Discuss short-term and long-term treatment goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

ACPE #: 0204-9999-21-912-H04-P

  • Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
  • Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

ACPE #: 0204-9999-21-928-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.

ACPE #: 0204-9999-21-925-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

ACPE #: 0204-9999-21-917-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic leukemia.
  • Determine appropriate pharmacotherapy based on genomic test results in a patient with chronic leukemia.
  • Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

ACPE #: 0204-9999-21-921-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
  • Apply appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies.
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

ACPE #: 0204-9999-21-923-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
  • Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.

ACPE #: 0204-9999-21-927-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

ACPE #: 0204-9999-21-930-H01-P

  • Design an appropriate patient-specific treatment, management and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS) malignancies, or thyroid cancers.
  • Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, and screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.

ACPE #: 0204-9999-21-931-H01-P

  • Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
  • Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

ACPE #: 0204-9999-21-920-H04-P

  • Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

ACPE #: 0204-9999-21-918-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression in all oncology patients.

ACPE #: 0204-9999-21-919-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

ACPE #: 0204-9999-21-913-H01-P

  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
  • Apply the results from somatic genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapeutic decision making for companion diagnostic testing.

Planners, Presenters and Reviewers

Faculty 

Jessica Auten, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina 

John Bossaer, Pharm.D., BCPS, BCOP
Associate Professor
Gatton College of Pharmacy at ETSU
Johnson City, Tennessee 

Courtney Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Brette Conliffe, Pharm.D., BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky 

Karen Fancher, Pharm.D., BCOP*
Assistant Professor of Pharmacy Practice
Dusquesne University School of Pharmacy
Pittsburgh, Pennsylvania 

Christopher Fausel, Pharm.D., M.H.A., BCOP
Clinical Manager - Oncology Pharmacy
Indiana University Health
Indianapolis, Indiana 

Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah 

Lauren Ice, Pharm.D., BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan 

Elyse MacDonald, Pharm.D., M.S., BCPS
Assistant Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California 

Janelle Mann, Pharm.D., BCOP
Clinical Oncology Pharmacist / Manager, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center / Washington University School of Medicine in St. Louis
St. Louis, Missouri 

Anthony Perissinotti, Pharm.D., BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan 

Tim Peterson, Pharm.D., BCOP
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York 

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine Walko, Pharm.D., BCOP, FCCP*
Associate Member, Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
H. Lee Moffitt Cancer Center
Tampa, Florida 

Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist - Pediatric Oncology
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 

*Content Matter Experts 

Reviewers

Courtney Alexander, Pharm.D., BCPS, BCOP
Jaime Anderson, BCOP, CMQ
Carrie Beckman, Pharm.D., BCPS, BCOP
Laura Bobolts, Pharm.D. BCOP
Salvatore Bottiglieri, Pharm.D., BCOP
Theresa Brown, Pharm.D. BCOP CPP
Joseph Bubalo, Pharm.D., BCOP, BCPS
Ryan Bycroft, Pharm.D., BCOP
Brandon Chang, Pharm.D., BCPS, BCOP
Jill Comeau, Pharm.D., BCOP
Vanessa Copeland, Pharm.D., BCOP
Wendy Covert, Pharm.D., BCOP
Sara DeHoll, Pharm.D., BCOP
Bryna  Delman Ewachiw, Pharm.D., BCOP
Seema Ganatra, Pharm.D., BCPS, BCOP
Sarah Gifford, Pharm.D, BCOP
Sean Green, Pharm.D., BCOP
Alyssa Heiden, Pharm.D., BCOP
Hansen Ho, Pharm.D. BCOP
Mitchell  Hughes, Pharm.D., BCPS, BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Lindsay Kaster, Pharm.D., BCOP
Jodi Lech, Pharm.D., BCOP
Matthew Lei, Pharm.D., BCOP
Samantha Luk, Pharm.D., BCOP
Morgan Mace, Pharm.D., BCOP
Lisa Modelevsky, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Nancy Nix, Pharm.D., BCPS, BCOP
Terry  Pak, Pharm.D., BCOP
Jeremy Pappacena, Pharm.D., BCOP
Seon Jo Park, Pharm.D.,BCOP
Jennifer Piccolo, Pharm.D., BCOP
Melvin Rivera, BCOP
Shreya Shah, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Zane Waite, Pharm.D., BCOP
Robert Wilkinson, Pharm.D., M.S., BCOP, BCPS
Lily Yan, Pharm.D., BCOP
Mark Zangardi, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen Fancher is Consultant, AstraZeneca, LP; Consultant, Merck & Co. 

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.